US2022177432A1PendingUtilityA1

Novel diamino pyridine derivatives

Assignee: NOVARTIS AGPriority: Nov 26, 2015Filed: Feb 22, 2022Published: Jun 9, 2022
Est. expiryNov 26, 2035(~9.3 yrs left)· nominal 20-yr term from priority
Inventors:Gebhard Thoma
A61P 11/00A61P 17/06A61P 21/04A61P 19/06A61P 7/04A61K 31/444C07D 213/74A61P 19/02A61P 11/02A61P 37/06C07D 401/12A61P 17/02C07D 213/82A61P 29/00A61P 25/00A61P 13/12A61P 11/04A61P 1/18A61P 5/18A61P 5/14A61P 37/08A61P 1/00A61P 1/04A61P 17/04A61P 43/00A61P 17/00A61P 3/10A61P 35/00A61P 9/10A61P 11/06
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention describes novel diamino pyridine derivatives exhibiting JAK modulating properties. The present invention also relates to pharmaceutical compositions comprising these novel compounds, methods of using said compounds in the treatment of various diseases and disorders being susceptible to JAK modulation, and processes for preparing the compounds described hereinafter.

Claims

exact text as granted — not AI-modified
1 . A combination comprising a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more therapeutically active co-agents; 
       
         
           
           
               
               
           
         
         wherein, 
         R 1  is H or C 1 -C 6  alkyl; and 
         Hal is halogen. 
       
     
     
         2 . The combination of  claim 1 , wherein Hal is chloro or fluoro. 
     
     
         3 . The combination of  claim 1 , wherein Hal is chloro. 
     
     
         4 . The combination of  claim 1 , wherein R 1  is methyl. 
     
     
         5 . The combination of  claim 1 , wherein R 1  is hydrogen. 
     
     
         6 . The combination of  claim 1 , wherein R 1  is methyl in position 6 of the associated pyridine ring. 
     
     
         7 . The combination of  claim 1 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is selected from
 4-((2-chlorophenyl)amino)-6-(pyridin-2-ylamino)nicotinamide; and   4-((2-chlorophenyl)amino)-6-((6-methylpyridin-2-yl)amino)nicotinamide.

Join the waitlist — get patent alerts

Track US2022177432A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.